188 related articles for article (PubMed ID: 33067535)
1. Evaluation of blood gene expression levels in facioscapulohumeral muscular dystrophy patients.
Signorelli M; Mason AG; Mul K; Evangelista T; Mei H; Voermans N; Tapscott SJ; Tsonaka R; van Engelen BGM; van der Maarel SM; Spitali P
Sci Rep; 2020 Oct; 10(1):17547. PubMed ID: 33067535
[TBL] [Abstract][Full Text] [Related]
2. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
Banerji CRS; Zammit PS
Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
[TBL] [Abstract][Full Text] [Related]
3. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
4. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
Banerji CRS; Zammit PS
EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
[TBL] [Abstract][Full Text] [Related]
5. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
van den Heuvel A; Lassche S; Mul K; Greco A; San León Granado D; Heerschap A; Küsters B; Tapscott SJ; Voermans NC; van Engelen BGM; van der Maarel SM
Sci Rep; 2022 Jan; 12(1):1426. PubMed ID: 35082321
[TBL] [Abstract][Full Text] [Related]
6. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
[TBL] [Abstract][Full Text] [Related]
7. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
[TBL] [Abstract][Full Text] [Related]
8. PAX7 target gene repression associates with FSHD progression and pathology over 1 year.
Banerji CRS
Hum Mol Genet; 2020 Aug; 29(13):2124-2133. PubMed ID: 32347924
[TBL] [Abstract][Full Text] [Related]
9. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
Haynes P; Kernan K; Zhou SL; Miller DG
Skelet Muscle; 2017 Jun; 7(1):13. PubMed ID: 28637492
[TBL] [Abstract][Full Text] [Related]
10. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies.
Wong CJ; Wang LH; Friedman SD; Shaw D; Campbell AE; Budech CB; Lewis LM; Lemmers RJFL; Statland JM; van der Maarel SM; Tawil RN; Tapscott SJ
Hum Mol Genet; 2020 Apr; 29(6):1030-1043. PubMed ID: 32083293
[TBL] [Abstract][Full Text] [Related]
12. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
14. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
15. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
Schätzl T; Kaiser L; Deigner HP
Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
[TBL] [Abstract][Full Text] [Related]
16. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
[TBL] [Abstract][Full Text] [Related]
17. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
18. Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies.
Greco A; Straasheijm KR; Mul K; van den Heuvel A; van der Maarel SM; Joosten LAB; van Engelen BGM; Pruijn GJM
J Neuromuscul Dis; 2021; 8(5):801-814. PubMed ID: 34024774
[TBL] [Abstract][Full Text] [Related]
19. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
Wang LH; Friedman SD; Shaw D; Snider L; Wong CJ; Budech CB; Poliachik SL; Gove NE; Lewis LM; Campbell AE; Lemmers RJFL; Maarel SM; Tapscott SJ; Tawil RN
Hum Mol Genet; 2019 Feb; 28(3):476-486. PubMed ID: 30312408
[TBL] [Abstract][Full Text] [Related]
20. p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy.
Bosnakovski D; Gearhart MD; Toso EA; Recht OO; Cucak A; Jain AK; Barton MC; Kyba M
Dis Model Mech; 2017 Oct; 10(10):1211-1216. PubMed ID: 28754837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]